Resveratrol Ameliorates Deep Vein Thrombosis-Induced Inflammatory Response Through Inhibiting HIF-1α/NLRP3 Pathway

Fei, Jianwen; Xiao, Qin; Ma, Hongfu; Zhang, Xuefeng; Wang, Haixia; Han, Jin Tae; Yu, Chaoxiao; Jiang, Junjie

doi:10.1007/s10753-022-01689-y

Cited by 5 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, Wei et al reported that GQPs conferred protection against carrageenan-induced thrombosis in mice via NLRP3 inhibition [148]. Resveratrol, a polyphenol found in red wine, reduced the expression of NLRP3 and diminished the severity of venous thrombosis in a murine model [149]. Emerging clinical studies further strengthened the evidence supporting the protective impact of NLRP3 inhibition against thrombosis and cardiovascular diseases.…”

Section: Inhibiting Nlrp3: a Promising Therapeutic Approach For Throm...mentioning

confidence: 94%

NLRP3-Induced NETosis: A Potential Therapeutic Target for Ischemic Thrombotic Diseases?

Kumar,

Patil,

Dayal

2023

Cells

View full text Add to dashboard Cite

Ischemic thrombotic disease, characterized by the formation of obstructive blood clots within arteries or veins, is a condition associated with life-threatening events, such as stroke, myocardial infarction, deep vein thrombosis, and pulmonary embolism. The conventional therapeutic strategy relies on treatments with anticoagulants that unfortunately pose an inherent risk of bleeding complications. These anticoagulants primarily target clotting factors, often overlooking upstream events, including the release of neutrophil extracellular traps (NETs). Neutrophils are integral components of the innate immune system, traditionally known for their role in combating pathogens through NET formation. Emerging evidence has now revealed that NETs contribute to a prothrombotic milieu by promoting platelet activation, increasing thrombin generation, and providing a scaffold for clot formation. Additionally, NET components enhance clot stability and resistance to fibrinolysis. Clinical and preclinical studies have underscored the mechanistic involvement of NETs in the pathogenesis of thrombotic complications, since the clots obtained from patients and experimental models consistently exhibit the presence of NETs. Given these insights, the inhibition of NETs or NET formation is emerging as a promising therapeutic approach for ischemic thrombotic diseases. Recent investigations also implicate a role for the nucleotide-binding oligomerization domain (NOD)-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome as a mediator of NETosis and thrombosis, suggesting that NLRP3 inhibition may also hold potential for mitigating thrombotic events. Therefore, future preclinical and clinical studies aimed at identifying and validating NLRP3 inhibition as a novel therapeutic intervention for thrombotic disorders are imperative.

show abstract

Section: Inhibiting Nlrp3: a Promising Therapeutic Approach For Throm...mentioning

confidence: 94%

NLRP3-Induced NETosis: A Potential Therapeutic Target for Ischemic Thrombotic Diseases?

Kumar,

Patil,

Dayal

2023

Cells

View full text Add to dashboard Cite

show abstract

“…Ai et al observed a decrease in the expression of miR-411, while the expressions of hypoxia-inducible factor-1α (HIF-1α), Collagen I, as well as MMP-2 were increased in the vein walls and corresponding VSMCs obtained from rats with DVT [40]. HIF-1α is known to play important roles in cell proliferation, migration, and differentiation; vasoconstriction or vasodilation; ECM degradation; and angiogenesis [41,42]. In addition, HIF-1α regulates many genes, and mediates vein wall fibrosis remodeling, implying HIF-1α might be a potential target for the treatment of vein wall fibrosis in DVT [43].…”

Section: Mirna and Dvtmentioning

confidence: 99%

MiRNAs and Their Role in Venous Thromboembolic Complications

Gareev,

Pavlov,

et al. 2023

Diagnostics

View full text Add to dashboard Cite

Venous thromboembolic complications (VTCs), which include deep vein thrombosis (DVT) and pulmonary embolism (PE), have remained a pressing problem in modern clinical medicine for a long time. Despite the already wide arsenal of modern methods for diagnosing and treating this disease, VTCs rank third in the structure of causes of death among all cardiovascular diseases, behind myocardial infarction (MI) and ischemic stroke (IS). Numerous studies have confirmed the importance of understanding the molecular processes of VTCs for effective therapy and diagnosis. Significant progress has been made in VTC research in recent years, where the relative contribution of microRNAs (miRNAs) in the mechanism of thrombus formation and their consideration as therapeutic targets have been well studied. In this case, accurate, timely, and as early as possible diagnosis of VTCs is of particular importance, which will help improve both short-term and long-term prognoses of patients. This case accounts for the already well-studied circulating miRNAs as non-invasive biomarkers. This study presents currently available literature data on the role of miRNAs in VTCs, revealing their potential as therapeutic targets and diagnostic and prognostic tools for this terrible disease.

show abstract

Resveratrol as sensitizer in colorectal cancer plasticity

Brockmueller

Sajeev

Koklesová

et al. 2023

Cancer Metastasis Rev

View full text Add to dashboard Cite

Despite tremendous medical treatment successes, colorectal cancer (CRC) remains a leading cause of cancer deaths worldwide. Chemotherapy as monotherapy can lead to significant side effects and chemoresistance that can be linked to several resistance-activating biological processes, including an increase in inflammation, cellular plasticity, multidrug resistance (MDR), inhibition of the sentinel gene p53, and apoptosis. As a consequence, tumor cells can escape the effectiveness of chemotherapeutic agents. This underscores the need for cross-target therapeutic approaches that are not only pharmacologically safe but also modulate multiple potent signaling pathways and sensitize cancer cells to overcome resistance to standard drugs. In recent years, scientists have been searching for natural compounds that can be used as chemosensitizers in addition to conventional medications for the synergistic treatment of CRC. Resveratrol, a natural polyphenolic phytoalexin found in various fruits and vegetables such as peanuts, berries, and red grapes, is one of the most effective natural chemopreventive agents. Abundant in vitro and in vivo studies have shown that resveratrol, in interaction with standard drugs, is an effective chemosensitizer for CRC cells to chemotherapeutic agents and thus prevents drug resistance by modulating multiple pathways, including transcription factors, epithelial-to-mesenchymal transition-plasticity, proliferation, metastasis, angiogenesis, cell cycle, and apoptosis. The ability of resveratrol to modify multiple subcellular pathways that may suppress cancer cell plasticity and reversal of chemoresistance are critical parameters for understanding its anti-cancer effects. In this review, we focus on the chemosensitizing properties of resveratrol in CRC and, thus, its potential importance as an additive to ongoing treatments. Graphical abstract

show abstract

Resveratrol Ameliorates Deep Vein Thrombosis-Induced Inflammatory Response Through Inhibiting HIF-1α/NLRP3 Pathway

Cited by 5 publications

References 27 publications

NLRP3-Induced NETosis: A Potential Therapeutic Target for Ischemic Thrombotic Diseases?

NLRP3-Induced NETosis: A Potential Therapeutic Target for Ischemic Thrombotic Diseases?

MiRNAs and Their Role in Venous Thromboembolic Complications

Resveratrol as sensitizer in colorectal cancer plasticity

Contact Info

Product

Resources

About